Status and phase
Conditions
Treatments
About
The study will evaluate the efficacy, safety, and tolerability of 450 milligrams (mg) of Rapastinel, compared to placebo in adult patients with major depressive disorder (MDD) who are at imminent risk of suicide.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
DSM-5-based diagnosis of any disorder other than MDD that was the primary focus of treatment within 1 month before Visit 1.
Lifetime history or currently meet DSM-5 criteria for:
Significant homicidal ideation or at imminent risk of injuring others or causing significant damage to property, as judged by the investigator.
Prior participation in any investigational study of rapastinel/GLYX-13
Primary purpose
Allocation
Interventional model
Masking
138 participants in 2 patient groups, including a placebo group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal